ClinicalTrials.gg
CompletedNCT07036458Updated Apr 23, 2026

To Evaluate the Mass Balance Recovery, Metabolite Profile and Metabolite Identification in Healthy Male Subjects

A Phase 1 interventional study of 14C Epaminurad Oral Solution in Healthy Male Adults, sponsored by JW Pharmaceutical. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by JW Pharmaceutical · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
30 Years to 65 Years
Sex
Male
01

Study summary

To Evaluate the Mass Balance Recovery, Metabolite Profile and Metabolite Identification in Healthy Male Subjects

Read the detailed description

The following blood, urine and faecal samples will be collected, and assessments performed, at specified time points

02

Conditions studied

  • Healthy Male Adults
03

In context

Lead sponsor

JW Pharmaceutical is the lead sponsor of 77 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Healthy volunteers

Exclusion criteria

Exclusion Criteria:

1. Subjects does not meet the Inclusion Criteria

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Other
    Subjects will receive a single administration of 14C Epaminurad Oral Solution

    Drug: 14C Epaminurad Oral Solution

Interventions

  • Drug14C Epaminurad Oral Solution

    Subjects will receive a single administration of 14C Epaminurad Oral Solution

06

What researchers measure

Primary outcomes

  1. Mass balance recovery of total radioactivity in all excreta (urine and faeces)

    Collection of plasma, urine and faeces samples during time frame point

    Time frame: Baseline to Day 8

  2. Metabolite profling and structural identification

    Collection of plasma, urine and faeces samples during time frame point

    Time frame: Baseline to Day 8

07

Study locations

1 site
  • Quotient Science
    Nottingham, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Sep 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2025
First posted
Jun 25, 2025
StartActual
Aug 22, 2025
Primary completionActual
Sep 5, 2025
CompletionActual
Sep 5, 2025
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07036458
Lead sponsor
JW Pharmaceutical
Responsible party
Sponsor
First posted
Jun 25, 2025
Start date
Aug 22, 2025
Primary completion
Sep 5, 2025
Completion
Sep 5, 2025
Last update
Apr 23, 2026

Study contacts

McKenzie Litza, Principal Investigator
principal investigator · Quotient Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion